Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1308469 | 0.84 | GAA (0.53) | GAALMNAALDH1A1MAPTNPC1 | |
| SCHEMBL1310239 | 0.83 | MAPT (0.43) | LMNAALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL12114236 | 0.82 | SCN10A (0.47) | LMNAALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL1307860 | 0.81 | GPR35 (0.56) | NPC1RAB9ATP53KMT2AMEN1 | |
| SCHEMBL1310067 | 0.80 | KMT2A (0.49) | GAALMNAALDH1A1MAPTHTT | |
| SCHEMBL1308138 | 0.80 | KCNMA1 (0.58) | LMNAALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL1308444 | 0.79 | KCNMA1 (0.54) | MAPTKMT2AMEN1KDM4E | |
| SCHEMBL1309458 | 0.79 | GPR35 (0.58) | GAALMNAALDH1A1MAPTNPC1 | |
| SCHEMBL1307833 | 0.79 | GPR35 (0.54) | GAAALDH1A1NPC1RAB9ATP53 | |
| SCHEMBL1310065 | 0.79 | TSHR (0.63) | GAAALDH1A1MAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940792-B1 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES AS INHIBITORS OF PIM-1 AND/OR PIM-3 | EXELIXIS INC (US) | 2014-06-04 | — | — | EP | claimed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | claimed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| EP-1940792-A2 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES INHIBITORS OF PIM-1 AND/OR PIM-3 | Exelixis, Inc. (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007044724-A2 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES INHIBITORS OF PIM-I AND/OR PIM-3 | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| EP-1940792-B1 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES AS INHIBITORS OF PIM-1 AND/OR PIM-3 | EXELIXIS INC (US) | 2014-06-04 | — | — | EP | disclosed |
| EP-1940792-B1 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES AS INHIBITORS OF PIM-1 AND/OR PIM-3 | EXELIXIS INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2007044724-A2 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES INHIBITORS OF PIM-I AND/OR PIM-3 | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | GAA 2209/4885LMNA 1387/4885ALDH1A1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.